Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, Alliance Global Partners raised their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.17 on Monday. The stock has a market cap of $494,183.00, a P/E ratio of 0.00 and a beta of 2.08. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The firm has a fifty day moving average price of $0.19 and a 200 day moving average price of $1.91. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. The firm had revenue of $2.21 million during the quarter, compared to analyst estimates of $3.50 million. Equities research analysts anticipate that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.